Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 7/20 | 0.55 |
| ▸ | IKBKB | O14920 | 4/20 | 0.55 |
| ▸ | RARG | P13631 | 9/20 | 0.46 |
| ▸ | RARB | P10826 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.34 |
| ▸ | GOT1 | P17174 | 1/20 | 0.34 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5888161 | 1.00 | RARA (0.55) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5887866 | 0.90 | RARA (0.64) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL7753767 | 0.90 | RARA (0.64) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5888243 | 0.90 | RARA (0.64) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5887993 | 0.89 | RARA (0.62) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5888004 | 0.81 | RARA (0.67) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5887935 | 0.81 | RARA (0.60) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5887942 | 0.81 | RARA (0.60) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5887938 | 0.80 | RARA (0.76) | RARAIKBKBRARGRARBMEN1 | |
| SCHEMBL5887816 | 0.80 | RARA (0.66) | RARAIKBKBRARGRARBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992095-B2 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-04-08 | — | — | US | disclosed |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | BERNARDON JEAN-MICHEL (FR) | 2002-01-24 | — | — | US | disclosed |
| US-6214878-B1 | SKIN DISORDERS; RHEUMATIC DISEASES; RESPIRATORY SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; VISION DEFECTS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2001-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067971-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RARA 1151/4885IKBKB 485/4885RARG 1564/4885 |
| US-20020010337-A1 | Stilbene compounds comprising an adamantyl group, compositions and methods thereof | SQLE, FDFT1, PIGS | RARA 1151/4885IKBKB 485/4885RARG 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.